Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer
Open accessAbstract
BACKGROUND.: The use of androgen deprivation therapy (ADT) in the treatment of men with prostate cancer has risen sharply. Although cardiovascular disease is the most common reason for death among men with prostate cancer who do not die of the disease itself, data regarding the effect of ADT on cardiovascular morbidity and mortality in men with prostate cancer are limited. In the current study, the authors attempted to measure the risk for subsequent cardiovascular morbidity in men with prostate cancer who received ADT. METHODS.: A cohort of newly diagnosed men in a population‐based registry who were diagnosed between 1992 and 1996 were identified retrospectively. A total of 22,816 subjects were identified after exclusion criteria were applied. Using a multivariate model, the authors calculated the risk of subsequent cardiovascular morbidity in men with prostate cancer who were treated with ADT, as defined using Medicare claims. RESULTS.: Newly diagnosed prostate cancer patients who received ADT for at least 1 year were found to have a 20% higher risk of serious cardiovascular morbidity compared with similar men who did not receive ADT. Subjects began incurring this higher risk within 12 months of treatment. However, Hispanic men were found to have a lowered risk for cardiovascular morbidity. CONCLUSIONS.: ADT is associated with significantly increased cardiovascular morbidity in men with prostate cancer and may lower overall survival in men with low‐risk disease. These data have particular relevance to decisions regarding the use of ADT in men with prostate cancer in settings in which the benefit has not been clearly established. For men with metastatic disease, focused efforts to reduce cardiac risk factors through diet, exercise, or the use of lipid‐lowering agents may mitigate some of the risks of ADT. Cancer 2007. © 2007 American Cancer Society.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Development of a comorbidity index using physician claims data
Klabunde, C. N., Potosky, A. L., Legler, J. M., & Warren, J. L. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00256-0 · Cited by 1,846 · see citing works
Bolla, M., Collette, L., Blank, L., Warde, P., Dubois, J. B., Mirimanoff, R.-O., Storme, G., Bernier, J., Kuten, A., Sternberg, C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09408-4 · Cited by 1,686 · see citing works
Lantz, P. M., House, J. S., Lepkowski, J. M., Williams, D. R., Mero, R. P., & Chen, J. (1998) · JAMA · doi:10.1001/jama.279.21.1703 · Cited by 1,514 · see citing works
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2497 · Cited by 1,455 · see citing works
Risk of Fracture after Androgen Deprivation for Prostate Cancer
Shahinian, V. B., Kuo, Y., Freeman, J. L., & Goodwin, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa041943 · Cited by 1,375 · see citing works
Changes in body composition during androgen deprivation therapy for prostate cancer
Smith, M. R., Finkelstein, J. S., McGovern, F. J., Zietman, A. L., Fallon, M. A., Schoenfeld, D. A., & Kantoff, P. W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.2.8299 · Cited by 697 · see citing works
Potosky, A. L., Riley, G. F., Lubitz, J. D., Mentnech, R., & Kessler, L. G. (1993) · Medical Care · doi:10.1097/00005650-199308000-00006 · Cited by 695 · see citing works
English, K. M., Steeds, R. P., Jones, T. H., Diver, M. J., & Channer, K. S. (2000) · Circulation · doi:10.1161/01.cir.102.16.1906 · Cited by 582 · see citing works
Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of Age
Snyder, P. J. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.8.2647 · Cited by 531 · see citing works
Hak, A. E., Witteman, J. C. M., de Jong, F. H., Geerlings, M. I., Albert Hofman, D., & Pols, H. A. P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.8.3632 · Cited by 480 · see citing works
Mortality by Hispanic status in the United States.
Sorlie, P., Backlund, E., Johnson, N., & Rogot, E. (1993) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.1993.03510200070034 · Cited by 472 · see citing works
Wang, C. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.8.2839 · Cited by 359 · see citing works
National Practice Patterns and Time Trends in Androgen Ablation for Localized Prostate Cancer
Cooperberg, M. R., Grossfeld, G. D., Lubeck, D. P., & Carroll, P. R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.13.981 · Cited by 330 · see citing works
Insulin Resistance, Body Fat Distribution, and Sex Hormones in Men
Haffner, S. M., Karhapää, P., Mykkänen, L. M., & Laakso, M. (1994) · Diabetes · doi:10.2337/diab.43.2.212 · Cited by 305 · see citing works
Byar, D. P., & Corle, D. K. (1989) · The Journal of Urology · doi:10.1016/s0022-5347(17)41100-1 · Cited by 304 · see citing works
Testosterone, body composition and aging.
Vermeulen, A. T., Goemaere, S., & Kaufman, J. (1999) · PubMed · Cited by 280 · see citing works
Steen, B. C. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1988.tb05386.x · Cited by 259 · see citing works
Natural Androgens Inhibit Male Atherosclerosis
Alexandersen, P., Haarbo, J., Byrjalsen, I., Lawaetz, H., & Christiansen, C. (1999) · Circulation Research · doi:10.1161/01.res.84.7.813 · Cited by 251 · see citing works
Intramuscular testosterone esters and plasma lipids in hypogonadal men: a meta-analysis
Whitsel, E. A., Boyko, E. J., Matsumoto, A. M., Anawalt, B. D., & Siscovick, D. S. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00833-6 · Cited by 240 · see citing works
The relationship of natural androgens to coronary heart disease in males: a review
Alexandersen, P., Haarbo, J., & Christiansen, C. (1996) · Atherosclerosis · doi:10.1016/0021-9150(96)05864-9 · Cited by 239 · see citing works
Haffner, S. M., Valdez, R. A., Mykkänen, L., Stern, M. P., & Katz, M. S. (1994) · Metabolism · doi:10.1016/0026-0495(94)90202-x · Cited by 226 · see citing works
Jones, R. D., Pugh, P. J., Jones, T. H., & Channer, K. S. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705141 · Cited by 153 · see citing works
Lee, H., McGovern, K., Finkelstein, J. S., & Smith, M. R. (2005) · Cancer · doi:10.1002/cncr.21381 · Cited by 148 · see citing works
Shishehbor, M. H. (2006) · JAMA · doi:10.1001/jama.295.7.784 · Cited by 145 · see citing works
Byar, D. P., & Corle, D. K. (1988) · PubMed · Cited by 139 · see citing works
Plasminogen activator inhibitor in plasma is related to testosterone in men
Caron, P. J., Bennet, A., Camaré, R., et al. (1989) · Metabolism · doi:10.1016/0026-0495(89)90014-0 · Cited by 114 · see citing works
Sz, W., & Xz, W. (1993) · PubMed · Cited by 107 · see citing works
Becker, T. M., Wiggins, C. L., Key, C. R., & Samet, J. M. (1988) · Circulation · doi:10.1161/01.cir.78.2.302 · Cited by 90 · see citing works
Brenner, H., & Arndt, V. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.148 · Cited by 88 · see citing works
Nilsson, P. M., Nilsson, J., & Berglund, G. (2006) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01671.x · Cited by 85 · see citing works
Larsen, B. A., Nordestgaard, B. G., Stender, S., et al. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90053-w · Cited by 80 · see citing works
Tayek, J., Heber, D., Byerley, L., Steiner, B., Rajfer, J., & Swerdloff, R. S. (1990) · Metabolism: Clinical and Experimental · doi:10.1016/0026-0495(90)90190-n · Cited by 78 · see citing works
Rewers, M., Shetterly, S. M., Hoag, S., Baxter, J., Marshall, J., & Hamman, R. F. (1993) · PubMed · Cited by 70 · see citing works
Pugh, P. J., Channer, K. S., Parry, H., et al. (2002) · Endocrine Research · doi:10.1081/erc-120015055 · Cited by 40 · see citing works
The third analysis of the bicalutamide Early Prostate Cancer programme
Iversen, P., & on behalf of the Early Prostate Cancer programme investigators (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06118.x · Cited by 13 · see citing works
Owens, M., & Cimino, C. (1985) · Blood · doi:10.1182/blood.v66.2.402.402 · Cited by 10 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [5]5. Satariano WA, Ragland KE, Van Den Eeden SK. Cause of death in men diagnosed with prostate carcinoma. Cancer. 1998;83:1180-1188.
Cited by
Sorted by citations
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · see citing works
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945 · see citing works
Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., & Newton, R. U. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2488 · Cited by 657 · see citing works
Keating, N. L., O'Malley, A. J., Freedland, S. J., & Smith, M. R. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp404 · Cited by 622 · see citing works
Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study
Corona, G., Rastrelli, G., Monami, M., Guay, A., Buvat, J., Sforza, A., Forti, G., Mannucci, E., & Maggi, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0447 · Cited by 435 · see citing works
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., & Zakai, N. (2010) · Circulation · doi:10.1161/circulationaha.109.192695 · Cited by 383 · see citing works
Endocrine Aspects of Male Sexual Dysfunctions
Buvat, J., Maggi, M., Gooren, L., Guay, A. T., Kaufman, J., Morgentaler, A., Schulman, C., Tan, H. M., Torres, L. O., Yassin, A., et al. (2010) · The Journal of Sexual Medicine · doi:10.1111/j.1743-6109.2010.01780.x · Cited by 221 · see citing works
Galvão, D. A., Taaffe, D. R., Spry, N., Joseph, D., Turner, D., & Newton, R. U. (2009) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2008.51 · Cited by 198 · see citing works
Levine, G. N., D'Amico, A. V., Berger, P., Clark, P. E., Eckel, R. H., Keating, N. L., Milani, R. V., Sagalowsky, A. I., Smith, M. R., Zakai, N., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20061 · Cited by 188 · see citing works
Management of Complications of Prostate Cancer Treatment
Michaelson, M. D., Cotter, S. E., Gargollo, P. C., Zietman, A. L., Dahl, D. M., & Smith, M. R. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0002 · Cited by 196 · see citing works
Dawson, J. K., Dorff, T. B., Todd Schroeder, E., Lane, C. J., Gross, M. E., & Dieli-Conwright, C. M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4306-9 · Cited by 112 · see citing works
Management of side effects of androgen deprivation therapy
Grossmann, M., & Zajac, J. D. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.004 · Cited by 69 · see citing works
Napora, J. K., Short, R. G., Muller, D. C., Carlson, O. D., Odetunde, J. O., Xu, X., Carducci, M., Travison, T. G., Maggio, M., Egan, J. M., et al. (2011) · Journal of Andrology · doi:10.2164/jandrol.110.010983 · Cited by 35 · see citing works
Galvão, D. A., Newton, R. U., Taaffe, D. R., & Spry, N. (2008) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1104 · Cited by 31 · see citing works
- Authors
- Saigal, C. S., Gore, J. L., Krupski, T. L., Hanley, J., Schonlau, M., & Litwin, M. S.
- Affiliations
- University of California, Los Angeles (US)
- Duke University (US)
- RAND Corporation (US)
- Corresponding author
- Saigal, Christopher S.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-07-26
- Volume
- 110
- Issue
- 7
- Pages
- 1493-1500
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2105310697
- Semantic Scholar
- d42d90565d8a0be475529ec9e3eaa93c2378b4fd
- Cited by
- 542
- References
- 37
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 15 · 2023: 17 · 2022: 19 · 2021: 20 · 2020: 20 · 2019: 15 · 2018: 17 · 2017: 28 · 2016: 28 · 2015: 25 · 2014: 27 · 2013: 32 · 2012: 65
- FWCI
- 39.17
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute
- National Institute of Diabetes and Digestive and Kidney Diseases
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Keywords
- androgen deprivation therapy, prostate cancer, cardiovascular morbidity, cardiovascular risk, Hispanic men, low-risk prostate cancer, metastatic prostate cancer, overall survival, lipid-lowering drugs, cardiovascular risk factors
- MeSH terms
- Aged, Aged, 80 and over, Androgen Antagonists, Cardiovascular Diseases, Educational Status, Medicare, Hispanic or Latino, Humans, Male, Prostatic Neoplasms, Retrospective Studies, Risk Factors, Socioeconomic Factors, United States, Cohort Studies, Multivariate Analysis, SEER Program, Risk Assessment, Antineoplastic Agents, Hormonal, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
